Considerations of sex and gender differences in preclinical and clinical trials

Handbook of Experimental Pharmacology

Volumn 214, Issue , 2012, Pages 127-147

  Raz, Limor ^a   Miller, Virginia M ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Animal studies; Cultured cells; Definitions; Legislation; Phase I; Phase II; Phase III; Statistical analysis

Indexed keywords

ROSIGLITAZONE; TROGLITAZONE;

ADVERSE DRUG REACTION; ARTICLE; AUSTRALIA; CANADA; CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DIABETES MELLITUS; DRUG SAFETY; EUROPE; EXPERIMENTATION; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; JAPAN; LIVER FAILURE; MEDICAL ETHICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PARTICIPATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PRODUCT RECALL; RESEARCH SUBJECT; SEX DIFFERENCE; STATISTICAL ANALYSIS; STUDY DESIGN; UNITED STATES; VULNERABLE POPULATION; ANIMAL; DRUG SCREENING; FEMALE; MALE; METHODOLOGY; REVIEW; SEXUAL DEVELOPMENT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; MALE; RESEARCH DESIGN; SEX CHARACTERISTICS;

EID: 84868318908     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-30726-3_7     Document Type: Article

References (118)

1. Adams CP, Brantner VV (2006) Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25:420-428
2. Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B (1998) Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc 46:444-452
3. Ajayi AA, Hercule H, Cory J, Hayes BE, Oyekan AO (2003) Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes Res Clin Pract 59:11-24
4. Antoniucci D, Miller VM, Sieck GC, Fitzpatrick LA (2001) Gender-related differences in proliferative responses of vascular smooth muscle cells to endothelin-1. Endothelium 8:137-145
5. Arain FA, Kuniyoshi FH, Abdalrhim AD, Miller VM (2009) Sex/gender medicine: the biological basis for personalized care in cardiovascular medicine. Circ J 73:1774-1782
6. Arrigoni C, Crivori P (2007) Assessment of QT liabilities in drug development. Cell Biol Toxicol 23:1-13
7. Ashton Z (2000) The FDA: a short history. Women Alive:6-7
8. Avner P, Heard E (2001) X-chromosome inactivation: counting, choice and initiation. Nat Rev Genet 2:59-67
9. Bai Y, Sun T, Ye P (2010) Age, gender and diabetic status are associated with effects of bone marrow cell therapy on recovery of left ventricular function after acute myocardial infarction: a systematic review and meta-analysis. Ageing Res Rev 9:418-423
10. Bairey Merz CN, Mark S, Boyan BD, Jacobs AK, Shah PK, Shaw LJ, Taylor D, Marban E (2010) Proceedings from the scientific symposium: sex differences in cardiovascular disease and implications for therapies. J Womens Health (Larchmt) 19:1059-1072
11. Ballantyne AJ, Rogers WA (2008) Fair inclusion of men and women in Australian clinical research: views from ethics committee chairs. Med J Aust 188:653-656
12. Barchiesi F, Lucchinetti E, Zaugg M, Ogunshola OO, Wright M, Meyer M, Rosselli M, Schaufelberger S, Gillespie DG, Jackson EK, Dubey RK (2010) Candidate genes and mechanisms for 2-methoxyestradiol-mediated vasoprotection. Hypertension 56:964-972
13. Baylis F (2010) Pregnant women deserve better. Nature 465:689-690
14. Baylis F, Kaposky C (2010) Wanted: inclusive guidelines for research involving pregnant women. J Obstet Gynaecol Can 32:473-476
15. Beal CC (2010) Gender and stroke symptoms: a review of the current literature. J Neurosci Nurs 42:80-87
16. Becker JB, Arnold AP, Berkley KJ, Blaustein JD, Eckel LA, Hampson E, Herman JP, Marts S, Sadee W, Steiner M, Taylor J, Young E (2005) Strategies and methods for research on sex differences in brain and behavior. Endocrinology 146:1650-1673
17. Bednar MM, Harrigan EP, Ruskin JN (2002) Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 89:1316-1319
18. Beery AK, Zucker I (2011) Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35:565-572
19. Berlin JA, Ellenberg SS (2009) Inclusion of women in clinical trials. BMC Med 7:56
20. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355:260-269
21. Broyles LM, Colbert AM, Erlen JA (2005) Medication practice and feminist thought: a theoretical and ethical response to adherence in HIV/AIDS. Bioethics 19:362-378
22. Caplan AL (2005) Too hard to face. J Am Acad Psychiatry Law 33:394-400
23. Col NF (2005) The impact of risk status, preexisting morbidity, and polypharmacy on treatment decisions concerning menopausal symptoms. The American journal of medicine 118 Suppl 12B:155-62
24. Collins JM, Grieshaber CK, Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82:1321-1326
25. Csaba G, Torok O, Kovacs P (1990) Permanence of the cell-to-cell transmission of insulin induced hormonal imprinting. Acta Physiol Hung 75:111-116
26. Curfman GD, Morrissey S, Drazen JM (2005) Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.
27. N Engl J Med 353:2813-2814
28. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22:151-185
29. Dodds WJ, Abelseth MK (1980) Criteria for selecting the animal to meet the research need. Lab Anim Sci 30:460-465
30. Drici MD, Clement N (2001) Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24:575-585
31. Druml C, Wolzt M, Pleiner J, Singer EA (2009) Research ethics committees in Europe: trials and tribulations. Intensive Care Med 35:1636-1640
32. Enserink M (2005) Let's talk about sex-and drugs. Science 308:1578
33. Fisher MR, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, Group ftS (2009) Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations. Stroke 40:2244-2249
34. Fleisch J, Fleisch MC, Thurmann PA (2005) Women in early-phase clinical drug trials: have things changed over the past 20 years? Clin Pharmacol Ther 78:445-452
35. Foulkes MA (2011) After inclusion, information and inference: reporting on clinical trials results after 15 years of monitoring inclusion of women. J Womens Health (Larchmt) 20:829-836
36. Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA (2011) Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. Int J Pharm 415:15-28
37. Frewer A (2010) Human rights from the Nuremberg doctors trial to the geneva declaration. Persons and institutions in medical ethics and history. Med Health Care Philos 13:259-268
38. Gall SL, Donnan G, Dewey HM, Macdonell R, Sturm J, Gilligan A, Srikanth V, Thrift AG (2010) Sex differences in presentation, severity, and management of stroke in a population-based study. Neurology 74:975-981
39. Geller SE, Adams MG, Carnes M (2006) Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. J Womens Health (Larchmt) 15:1123-1131
40. Geller SE, Koch A, Pellettieri B, Carnes M (2011) Inclusion, analysis and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health 20:315-320
41. Georges JM, Benedict S (2006) An ethics of testimony: prisoner nurses at Auschwitz. ANS Adv Nurs Sci 29:161-169
42. Ghooi RB (2011) The Nuremberg Code-A critique. Perspect Clin Res 2:72-76
43. Gillies GE, McArthur S (2010) Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev 62:155-198
44. Ginsburg GS, Willard HF (2009) Genomic and personalized medicine: foundations and applications. Transl Res 154:277-287
45. Gochfeld M (2010) Sex-gender research sensitivity and healthcare disparities. J Womens Health 19:189-194
46. Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB, Gold MS, Holdcroft A, Lautenbacher S, Mayer EA, Mogil JS, Murphy AZ, Traub RJ (2007) Studying sex and gender differences in pain and analgesia: a consensus report. Pain 132:S26-S45
47. Gregg EW, Gu Q, Cheng YJ, Naranayan KMV, Cowie CC (2007) Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 147:149-155
48. Hagberg H, Wilson MA, Matsushita H, Zhu C, Lange M, Gustavsson M, Poitras MF, Dawson TM, Dawson VL, Northington F, Johnston MV (2004) PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90:1068-1075
49. Hager R, Cheverud JM, Leamy LJ, Wolf JB (2008) Sex dependent imprinting effects on complex traits in mice. BMC Evol Biol 8:303
50. Hamburg MA, Collins FS (2010) The path to personalized medicine. N Engl J Med 363:301-304
51. Hammad TA, Pinheiro SP, Neyarapally GA (2011) Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations. Clin Trials 8:559-570
52. Hancox JC (2011) Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone. Br J Pharmacol 163:496-498
53. Harris DJ, Douglas PS (2000) Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 343:475-480
54. Harslof T, Wamberg L, Moller L, Stodkilde-Jorgensen H, Ringgaard S, Pedersen SB, Langdahl BL (2011) Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 96:1541-1548
55. Heinrich J (2001) GAO-01-286R drugs withdrawn from market. General Accounting Office, Washington, DC
56. Isensee J, Ruiz Noppinger P (2007) Sexually dimorphic gene expression in mammalian somatic tissue. Gend Med 4 Suppl B:S75-95
57. Isensee J, Witt H, Pregla R, Hetzer R, Regitz-Zagrosek V, Noppinger PR (2008) Sexually dimorphic gene expression in the heart of mice and men. J Mol Med 86:61-74
58. Ivanova T, Beyer C (2003) Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain. J Neurobiol 54:638-647
59. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL (1999) Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104:447-457
60. Joshi A, Dimino T, Vohra Y, Cui C, Yan GX (2004) Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 37 (Suppl):7-14
61. Kaplan JR, Manuck SB (1999) Status, stress, and atherosclerosis: the role of environment and individual behavior. Ann N Y Acad Sci 896:145-161
62. Kaplan JR, Manuck SB, Clarkson TB, Prichard RW (1985) Animal models of behavioral influences on atherogenesis. Adv Behav Med 1:115-163
63. Karbwang J, Torres C (2011) Ethical issues related to clinical trials outside the International Conference on Harmonization regions. Future Med Chem 3:1457-1460
64. Kim ES, Menon V (2009) Status of women in cardiovascular clinical trials. Arterioscler Thromb Vasc Biol 29:279-283
65. Kim AK, Tingen CM, Woodruff TK (2010) Sex bias in trials and treatment must end. Nature 465:688-689
66. Klein SL, Passaretti C, Anker M, Olukoya P, Pekosz A (2010) The impact of sex, gender and pregnancy on 2009 H1N1 disease. Biol Sex Differ 1:5
67. Kuehn BM (2010) Frances Kelsey honored for FDA legacy: award notes her work on thalidomide, clinical trials. JAMA 304(2109-10):2112
68. Lippman A (1995) "Never too late": biotechnology, women and reproduction. McGill Law J 40:875-891
69. Liu XK, Wang W, Ebert SN, Franz MR, Katchman A, Woosley RL (1999) Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol 34:287-294
70. Loblay RH (2008) Human research ethics - a work in progress. Med J Aust 188:628-629
71. Luczak ED, Barthe KK, Stauffer BL, Konhilas JP, Cheung TH, Leinwand LA (2011) Remodeling the cardiac transcriptional landscape with diet. Physiol Genomics 43:772-780
72. Macrae DJ (2007) The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials. Proc Am Thorac Soc 4:176-178, discussion 178-179
73. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD (2005) Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia; male toxicity, female protection. J Cereb Blood Flow Metab 25:502-512
74. McEwen BS (2001) Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol 91:2785-2801
75. Meinert CL, Gilpin AK, Unalp A, Dawson C (2000) Gender representation in trials. Control Clin Trials 21:462-475
76. Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS, Dolor RJ, Douglas PS, Mark DB, Newby LK (2010) Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes 3:135-142
77. Merkatz RB, Temple R, Subel S, Feiden K, Kessler DA (1993) Women in clinical trials of new drugs. A change in food and drug administration policy. The working group on women in clinical trials. N Engl J Med 329:292-296
78. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM (2009) Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2:228-239
79. Miller VM, de Vries G, Arnold A (2010) Sex and gender matters in drug development and life cycle management. Global Forum 2:82-83
80. Miller VM, Kaplan JR, Schork NJ, Ouyang P, Berga SL, Wenger NK, Shaw LJ, Webb RC, Mallampalli M, Steiner M, Taylor DA, Bairey Merz CN, Reckelhoff JF (2011) Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. Biol Sex Differ 2:14
81. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, Newby LK, Pina IL, Roger VL, Shaw LJ, Zhao D, Beckie TM, Bushnell C, D'Armiento J, Kris-Etherton PM, Fang J, Ganiats TG, Gomes AS, Gracia CR, Haan CK, Jackson EA, Judelson DR, Kelepouris E, Lavie CJ, Moore A, Nussmeier NA, Ofili E, Oparil S, Ouyang P, Pinn VW, Sherif K, Smith SC Jr, Sopko G, Chandra-Strobos N, Urbina EM, Vaccarino V, Wenger NK (2011) Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 123:1243-1262
82. Nieuwenhoven L, Klinge I (2010) Scientific excellence in applying sex- and gender-sensitive methods in biomedical and health research. J Womens Health 19:313-321
83. O'Neill RT (1995) Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization. Stat Med 14:117-127
84. Ober C, Loisel DA, Gilad Y (2008) Sex-specific genetic architecture of human disease. Nat Rev Genet 9:911-922
85. Ostrer H (1999) Sex-based differences in gene transmission and gene expression. Lupus 8:365-369
86. Parekh A, Fadiran EO, Uhl K, Throckmorton DC (2011) Adverse effects in women: implications for drug development and regulatory policies. Expert Rev Clin Pharmacol 4:453-466
87. Pierce JP, Kievits J, Graustein B, Speth RC, Iadecola C, Milner TA (2009) Sex differences in the subcellular distribution of angiotensin type 1 receptors and NADPH oxidase subunits in the dendrites of C1 neurons in the rat rostral ventrolateral medulla. Neuroscience 163:329-338
88. Pillay N (2008) Right to health and the Universal Declaration of Human Rights. Lancet 372:2005-2006
89. Puri KS, Suresh KR, Gogtay NJ, Thatte UM (2009) Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med 55:131-134
90. Regitz-Zagrosek V, Lehmkuhl E (2005) Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. Herz 30:356-367
91. Reichmann JP (2011) NIH: FDA key for speed and safety. Nature 474:161
92. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2012) Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 125:e2-e220
93. Rogers WA, Ballantyne AJ (2008) Exclusion of women from clinical research: myth or reality? Mayo Clinic proc 83:536-542
94. Rosenberger WF, Haines LM (2002) Competing designs for phase I clinical trials: a review. Stat Med 21:2757-2770
95. Ruiz Cantero MT, Angeles Pardo M (2006) European Medicines Agency policies for clinical trials leave women unprotected. J Epidemiol Community Health 60:911-913
96. Rzewuska-Lech E, Jayachandran M, Fitzpatrick LA, Miller VM (2005) Differential effects of 17b-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. Am J Physiol Endocrinol Metab 289:E105-E112
97. Scher HI, Nasso SF, Rubin EH, Simon R (2011) Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res 17:6634-6640
98. Seto-Young D, Avtanski D, Parikh G, Suwandhi P, Strizhevsky M, Araki T, Rosenwaks Z, Poretsky L (2011) Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. Horm Metab Res 43:250-256
99. Sharma MR, Stadler WM, Ratain MJ (2011) Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst 103:1093-1100
100. Siegel C, Turtzo C, McCullough LD (2010) Sex differences in cerebral ischemia: possible molecular mechanisms. J Neurosci Res 88:2765-2774
101. Smith PF (1996) Third international conference on harmonization of technical requirements for registration of pharmaceuticals for human use - a toxicologist's perspective. Toxicol Pathol 24:519-528
102. Taylor KE, Vallejo-Giraldo C, Schaible NS, Zakeri R, Miller VM (2011) Reporting of sex as a variable in cardiovascular studies using cultured cells. Biol Sex Differ 2:11
103. Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT (2011) The impact of cardiovascular disease prevalence on women's enrollment in landmark randomized cardiovascular trials: a systematic review. J Gen Intern Med 27(1):93-98
104. Umscheid CA, Margolis DJ, Grossman CE (2011) Key concepts of clinical trials: a narrative review. Postgrad Med 123:194-204
105. van Nas A, Ingram-Drake L, Sinsheimer JS, Wang SS, Schadt EE, Drake T, Lusis AJ (2010) Expression quantitative trait loci: replication, tissue- and sex-specificity in mice. Genetics 185:1059-1068
106. Wang S, Yehya N, Schadt EE, Wang H, Drake TA, Lusis AJ (2006) Genetic and genomic analysis of a fat mass trait with complex inheritance reveals marked sex specificity. PLoS Genet 2:e15
107. Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215-228
108. Waxman DJ, Dannan GA, Guengerich FP (1985) Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry (Mosc) 24:4409-4417
109. Weindling P (2001) The origins of informed consent: the International Scientific Commission on Medical War Crimes, and the Nuremburg code. Bull Hist Med 75:37-71
110. Wizemann T, Pardue M-L (2001a) Sex affects health. Exploring the biological contributions to human health: does sex matter? Report of the Institute of Medicine. National Academy Press, Washington, DC, pp 96-97
111. Wizemann TM, Pardue ML (2001b) Exploring the biological contributions to human health: does sex matter? Board on Health Sciences Policy. Institute of Medicine, Washington, DC
112. Yang PC, Clancy CE (2010) Effects of sex hormones on cardiac repolarization. J Cardiovasc Pharmacol 56:123-129
113. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA, Lusis AJ (2006) Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 16:995-1004
114. Yang Y, Carlin AS, Faustino PJ, Motta MI, Hamad ML, He R, Watanuki Y, Pinnow EE, Khan MA (2009) Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002. J Womens Health (Larchmt) 18:303-310
115. Yao J, Hamilton RT, Cadenas E, Brinton RD (2010) Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim Biophys Acta 1800:1121-1126
116. Yuan M, Siegel C, Zeng Z, Li J, Liu F, McCullough LD (2009) Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol 217:210-218
117. Zakeri R, Vallejo-Giraldo C, Taylor KE, Miller VM, Schaible NS (2011) Using heart failure with preserved ejection fraction to understand an 'omics approach to evaluating vascular dysfunction and cardiovascular disease. J. Neurol Neurophysiol S1. doi:10.4172/2155-9562.S1-006
118. Zucker I, Beery A (2010) Males still dominate animal studies. Nature 465:690